Abstract:Introduction: β-Amyloid protein (Aβ) putatively plays a seminal role in synaptic loss in Alzheimer's disease (AD). While there is no consensus regarding the synaptic-relevant species of Aβ, it is known that Aβ oligomers (AβOs) are noticeably increased in the early stages of AD, localizing at or within the synapse. In cell and animal models, AβOs have been shown to attach to synapses and instigate synapse dysfunction and deterioration. To establish the pathological mechanism of synaptic loss in AD, it will be important to identify the synaptic targets to which AβOs attach.Methods: An unbiased approach using far western ligand blots has identified three synaptic proteins to which AβOs specifically attach. These proteins (p100, p140, and p260) were subsequently enriched by detergent extraction, ultracentrifugation, and CHT-HPLC column separation, and sequenced by LC-MS/MS. P100, p140, and p260 were identified. These levels of AβOs targets in human AD and aging frontal cortexes were analyzed by quantitative proteomics and western-blot. The polyclonal antibody to AβOs was developed and used to block the toxicity of AβOs. The data were analyzed with one-way analysis of variance.Results: AβOs binding proteins p100, p140, and p260 were identified as Na/K-ATPase, synGap, and Shank3, respectively. α3-Na/K-ATPase, synGap, and Shank3 proteins showed loss in the postsynaptic density (PSD) of human AD frontal cortex. In short term experiments, oligomers of Aβ inhibited Na/K-ATPase at the synapse. Na/K-ATPase activity was restored by an antibody specific for soluble forms of Aβ. α3-Na/K-ATPase protein and synaptic β-amyloid peptides were pulled down from human AD synapses by co-immunoprecipitation. Results suggest synaptic dysfunction in early stages of AD may stem from inhibition of Na/K-ATPase activity by Aβ oligomers, while later stages could hypothetically result from disrupted synapse structure involving the PSD proteins synGap and Shank3.Conclusion: We identified three AβO binding proteins as α3-Na/K-ATPase, synGap, and Shank3. Soluble Aβ oligomers appear capable of attacking neurons via specific extracellular as well as intracellular synaptic proteins. Impact on these proteins hypothetically could lead to synaptic dysfunction and loss, and could serve as novel therapeutic targets for AD treatment by antibodies or other agents.

Physiological Roles of beta-amyloid in Regulating Synaptic Function: Implications for AD Pathophysiology

Progress in molecular mechanisms of β-amyloid peptides in alzheimer's disease

Role of Amyloid Β Protein Receptors in Mediating Synaptic Plasticity.

The Role of Intracellular Amyloid Beta in Alzheimer'S Disease

A Function of Amyloid-β in Mediating Activity-Dependent Axon/Synapse Competition May Unify Its Roles in Brain Physiology and Pathology

Intracellular A beta and its Pathological Role in Alzheimer's Disease: Lessons from the Cellular to Animal Model

Role of APP and Aβ in Synaptic Physiology.

Oligomeric Aβ-induced Synaptic Dysfunction in Alzheimer’s Disease

Proteomic Analysis Reveals Physiological Activities of Aβ Peptide for Alzheimer's Disease

Recent Progress in the Study of Intracellular Toxicity of Amyloid Beta Peptide in Alzheimer'S Disease

The role of pathological tau in synaptic dysfunction in Alzheimer’s diseases

Endophilin 1 Knockdown Prevents Synaptic Dysfunction Induced by Oligomeric Amyloid Β

Apolipoprotein E in Alzheimer's Disease: Focus on Synaptic Function and Therapeutic Strategy

Aβ induces astrocytic glutamate release, extrasynaptic NMDA receptor activation, and synaptic loss

Synaptic Activity Reduces Intraneuronal Aβ, Promotes APP Transport to Synapses, and Protects Against Aβ-Related Synaptic Alterations

Apolipoprotein E in Alzheimer’s Disease: Focus on Synaptic Function and Therapeutic Strategy

Amyloid Beta Oligomers Target to Extracellular and Intracellular Neuronal Synaptic Proteins in Alzheimer's Disease

Opposing roles of physiological and pathological amyloid-β on synapses in live human brain slice cultures

Regulation of beta‐amyloid for the treatment of Alzheimer's disease: Research progress of therapeutic strategies and bioactive compounds

Amyloid β protein forms ion channels: implications for Alzheimer's disease pathophysiology

The Amyloid-β Pathway in Alzheimer's Disease